EGFR and lung adenocarcinoma: For male patients with grade II–III and III lung adenocarcinoma, although there was a numerical difference in the incidence of EGFR mutations (20.0% for Asians and 7.1% for non-Asians), the number of patients was small and we did not detect a statistical significance (p = 0.28).